FTSE 100 news / Companies and sectors / GSK / 5 October 2026

GSK (GSK): news on Monday 5 October 2026

+6.0 strongly positive

Coverage centred on GSK's dealmaking, including a completed USD 2.3 billion acquisition and a $750 million myeloma therapy purchase, which adds to its pipeline. Some caution came from a report of risks around the Nuvalent deal.

What drove it

pipeline acquisitions
myeloma deal
Nuvalent deal risks

The 5 stories

Each headline's own score, strongest first. Links go to the publisher.

+7.5 RAPT stock ends as GSK completes USD 2.3 billion deal AD HOC NEWS
GSK completes USD 2.3 billion acquisition, strengthening its pipeline.
+7.0 GSK agrees to acquire myeloma therapy. GSK stock costs EUR 20.83 AD HOC NEWS
GSK acquiring a myeloma therapy expands its oncology pipeline.
+6.7 GSK (NYSE: GSK) Strikes $750 Million Deal To Acquire Trispecific T-Cell Engager From ChImagen Biosciences For Multiple Myeloma foreignpolicyjournal.com
$750 million deal adds a multiple myeloma T-cell engager.
−3.7 GSK stock trades at GBp 1,779.50 after Nuvalent deal risks emerge AD HOC NEWS
Share price story highlights risks emerging around the Nuvalent deal.
+3.0 AN2 Therapeutics Secures Extended Gates Foundation Funding For GSK Tuberculosis Collaboration Pulse 2.0
Extended funding for a TB collaboration involving GSK; modest positive, partner-focused.

GSK: every day · Pharma and healthcare on 5 October 2026 · FTSE 100 overview for the day